This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith, D S Articles by Magner, A Search for Related Content PubMed PubMed Citation Articles by Smith, D S Articles by Magner, A

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1989 May; 33(5): 646-648

Failure of zinc gluconate in treatment of acute upper respiratory tract infections.

D S Smith, E C Helzner, C E Nuttall Jr, M Collins, B A Rofman, D Ginsberg, C B Goswick and A Magner

Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104.

ABSTRACT

Zinc is a trace metal with in vitro activity against rhinovirus, the major etiologic agent in acute upper respiratory tract infections (URIs). A previous trial of zinc gluconate supported its efficacy in treating URIs, but the effectiveness of blinding was uncertain. We conducted a prospective randomized trial of zinc gluconate versus a taste-matched placebo of sucrose octaacetate. Lozenges containing either 23 mg of elemental zinc or placebo were taken every 2 h. Eleven URI symptoms were rated daily on a scale of 0 (not present) to 3 (severe). Duration of illness, reflected in the proportion of subjects remaining symptomatic on each day, was not significantly reduced (maximum difference of 12.6% on day 7, P = 0.09; 95% confidence interval, -6 to 31%) by either treatment. Severity of illness, assessed by using a summed severity score, was reduced incrementally by 7 to 8% on days 5 to 7 (P = 0.02) in subjects taking zinc. Adverse effects, mostly nausea and altered taste, were reported by 50% of subjects taking zinc. We conclude that while zinc gluconate may produce a small reduction in overall severity of symptoms, this is not clinically significant. Given the additional high incidence of adverse effects, zinc gluconate cannot be recommended for use in the treatment of acute URIs.

---

Antimicrob Agents Chemother. 1989 May; 33(5): 646-648

This article has been cited by other articles:

• Bolser, D. C. (2006). Cough Suppressant and Pharmacologic Protussive Therapy: ACCP Evidence-Based Clinical Practice Guidelines. Chest 129: 238S-249S [Abstract] [Full Text]  
• Suara, R. O., Crowe, J. E. Jr. (2004). Effect of Zinc Salts on Respiratory Syncytial Virus Replication. Antimicrob. Agents Chemother. 48: 783-790 [Abstract] [Full Text]  
• Mossad, S.B. (2003). Effect of zincum gluconicum nasal gel on the duration and symptom severity of the common cold in otherwise healthy adults. QJM 96: 35-43 [Abstract] [Full Text]  
• Prasad, A. S., Fitzgerald, J. T., Bao, B., Beck, F. W.J., Chandrasekar, P. H. (2000). Duration of Symptoms and Plasma Cytokine Levels in Patients with the Common Cold Treated with Zinc Acetate: A Randomized, Double-Blind, Placebo-Controlled Trial. ANN INTERN MED 133: 245-252 [Abstract] [Full Text]  
• Arens, M., Travis, S. (2000). Zinc Salts Inactivate Clinical Isolates of Herpes Simplex Virus In Vitro. J. Clin. Microbiol. 38: 1758-1762 [Abstract] [Full Text]  
• Baum, M. K., Shor-Posner, G., Campa, A. (2000). Zinc Status in Human Immunodeficiency Virus Infection. J. Nutr. 130: 1421S-1423 [Abstract] [Full Text]  
• Jackson, J. L., Lesho, E., Peterson, C. (2000). Zinc and the Common Cold: A Meta-Analysis Revisited. J. Nutr. 130: 1512S-1515 [Abstract] [Full Text]  
• Macknin, M. L., Piedmonte, M., Calendine, C., Janosky, J., Wald, E. (1998). Zinc Gluconate Lozenges for Treating the Common Cold in Children: A Randomized Controlled Trial. JAMA 279: 1962-1967 [Abstract] [Full Text]  
• Jackson, J. L., Peterson, C., Lesho, E. (1997). A Meta-analysis of Zinc Salts Lozenges and the Common Cold. Arch Intern Med 157: 2373-2376 [Abstract]